Patient demographics, IGF-1 levels at 31, 32 and 33 weeks corrected GA, severity of ROP and ME
| Number | GA (weeks) | BW (g) | SDS score at birth | AWG (g) | SDS score at 6 weeks | IGF-1 levels at 31 weeks (μmol/L) | IGF-1 levels at 32 weeks (μmol/L) | IGF-1 levels at 33 weeks (μmol/L) | |
|---|---|---|---|---|---|---|---|---|---|
| All babies | 36 | 26.4 (1.9) | 846 (235) | −0.5 (1.1) | 566 (232) | −1.6 (0.9) | 13.6 (8.2) | 15.8 (10.3) | 20.1 (13.9) |
| ROP stages | |||||||||
| 0–1 | 14 | 28.1 (1.2) | 1026 (193) | −0.6 (1.3) | 704 (184) | −1.4 (1.0) | 14.3 (9.9) | 21.6 (12.3) | 27.5 (16.4) |
| 2 | 13 | 25.9 (1.5) | 781 (188) | −0.6 (1.0) | 535 (245) | −1.7 (0.8) | 12.6 (5.1) | 10.6 (4.6) | 13.7 (7.7) |
| 3 or Type 1 | 9 | 24.5 (1.0)** | 661 (163)** | −0.4 (0.9) | 397 (153)** | −1.9 (0.9) | 13.9 (9.9) | 14.3 (8.7)* | 17.6 (11.9)* |
| ME | |||||||||
| Asian | 15 | 26.1 (2.0) | 842 (274) | −0.5 (1.0) | 553 (222) | −1.6 (1.0) | 16.8 (8.8) | 19.6 (12.7) | 25.2 (17.0) |
| White | 15 | 27.0 (1.8) | 911 (205) | −0.5 (1.1) | 639 (241) | −1.5 (0.8) | 11.9 (7.2) | 14.8 (7.7) | 19.3 (9.8) |
| Black | 6 | 25.7 (2.0) | 694 (139) | −0.9 (1.3) | 418 (182) | −2.3 (0.6) | 9.7 (7.5) | 8.8 (3.1) | 9.4 (5.6)§ |
| Non-black (Asian or white) | 30 | 26.6 (1.9) | 877 (240) | −0.5 (1.0) | 596 (232) | −1.5 (0.9)* | 14.3 (8.3) | 17.2 (10.6)** | 22.3 (14.1)** |
Birth weight (BW), gestational age (GA), absolute weight gain in 6 weeks (AWG), maternal ethnicity (ME) and ROP stages (minimal ROP, Stage 0–1; ROP, Stage 2; ROP-proliferative stage (ie, Stage 3 or Type 1 ROP) of entire study cohort of babies. Data are shown as mean (SD). The values for ROP stages and ME were compared using analysis of variance (ANOVA). The values for non-black infants were compared with black infants using t test.
**p<0.01, *p<0.05, §p=0.05.
IGF-1, insulin-like growth factor 1; ROP, retinopathy of prematurity; SDS, SD scores.